2′,3′,5′-Tri-O-acetyluridine CAS 4105-38-8

• Iden­ti­fi­ca­tion
• Prop­er­ties
• Safe­ty Data
• Spec­i­fi­ca­tions & Oth­er Information
• Links
• Quick Inquiry

Iden­ti­fi­ca­tion

CAS Number

4105-38-8

Name

2′,3′,5′-Tri-O-acetyluridine

Syn­onyms

2′,3′,5′-Triacetyluridine
223-881-5
[EINECS]
2WP61F175M
[UNII]
2′,3′,5-TRI-ACETY­LURI­DINE
2′,3′,5′-Tri-O-acetyluridin
[Ger­man]
[IUPAC name – gen­er­at­ed by ACD/​Name]
2′,3′,5′-Tri-O-acetyluridine
[IUPAC name – gen­er­at­ed by ACD/​Name]
2′,3′,5′-Tri-O-acétyluridine
[French]
[IUPAC name – gen­er­at­ed by ACD/​Name]
2′,3′,5′-triacetate uri­dine
2′,3′,5′-Triacetyluridine
4105-38-8
[RN]
tri­acé­tate d’uridine
[French]
[INN]
tri­ac­eta­to de urid­i­na
[Span­ish]
[INN]
Uri­dine 2′,3′,5′-triacetate
uri­dine tri­ac­etate
[INN]
[USAN]
Uri­dine, 2′,3′,5′-triacetate
[Index name – gen­er­at­ed by ACD/​Name]
uri­di­ni tri­ac­etas
[Latin]
[INN]
Vis­tog­a­rd
[Trade name]
Xuri­den
[Trade name]

SMILES

CC(=O)OC[C@H]1OC@@HC@H[C@@H]1OC(C)=O

Std­InChI

InChI=1S/C15H18N2O9/c1-7(18)23-6-10-12(24-8(2)19)13(25-9(3)20)14(26-10)17-5-4-11(21)16-15(17)22/h4-5,10,12-14H,6H2,1-3H3,(H,16,21,22)/t10-,12-,13-,14-/m1/s1

Std­InChIKey

AUFUWRKPQL­GT­GF-FMK­­GYK­FT­SA-N

Mol­e­c­u­lar Formula

C₁₅H₁₈N₂O₉

Mol­e­c­u­lar Weight

370.319

EINECS

223-881-5

MDL Number

MFCD07798677

Prop­er­ties

Appear­ance

White or almost white crys­talline powder

Safe­ty Data

RIDADR 

NONH for all modes of transport

Spec­i­fi­ca­tions and Oth­er Infor­ma­tion of Our 2′,3′,5′-Tri-O-acetyluridine CAS 4105-38-8

Iden­ti­fi­ca­tion Methods

HNMR, HPLC

Puri­ty

≥98%

Heavy Metals(As Pb)

≤0.002%

Loss on Drying

≤1.0%

Residue on Ignition

≤0.20%

Shelf Life

3 years

Stor­age

Store at room tem­per­a­ture, Sealed and away from light.

Known Appli­ca­tion

1. Treat­ment of Hered­i­tary Orot­ic Aciduria This prod­uct is an orphan drug indi­cat­ed for the treat­ment of the rare genet­ic dis­or­der, hered­i­tary orot­ic aciduria. It func­tions by replen­ish­ing endoge­nous uri­dine lev­els, cor­rect­ing meta­bol­ic dis­tur­bances, and ame­lio­rat­ing asso­ci­at­ed hematopoi­et­ic and growth abnor­mal­i­ties in patients. 2. Chemother­a­py Anti­dote Specif­i­cal­ly indi­cat­ed for the man­age­ment of tox­i­c­i­ty result­ing from over­dos­es of the chemother­a­peu­tic agents 5-flu­o­rouracil and capecitabine. It serves to alle­vi­ate severe adverse effects induced by chemother­a­py, includ­ing car­diac, neu­ro­log­i­cal, and gas­troin­testi­nal tox­i­c­i­ties, as well as neutropenia.

Links

This prod­uct is devel­oped by our R&D com­pa­ny Cam­ing Phar­ma­ceu­ti­cal Ltd (https://​www​.cam​ing​.com/).

Quick Inquiry

Fill out our inquiry form and one of our experts will be in touch with you shortly.